<SEC-DOCUMENT>0000899243-19-002252.txt : 20190131
<SEC-HEADER>0000899243-19-002252.hdr.sgml : 20190131
<ACCEPTANCE-DATETIME>20190131165418
ACCESSION NUMBER:		0000899243-19-002252
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190129
FILED AS OF DATE:		20190131
DATE AS OF CHANGE:		20190131

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Canaan VIII LP
		CENTRAL INDEX KEY:			0001419148
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38386
		FILM NUMBER:		19556482

	BUSINESS ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE
		STREET 2:		STE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880
		BUSINESS PHONE:		203-855-0400

	MAIL ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE
		STREET 2:		STE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Canaan Partners VIII LLC
		CENTRAL INDEX KEY:			0001552200
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38386
		FILM NUMBER:		19556483

	BUSINESS ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE
		STREET 2:		STE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880
		BUSINESS PHONE:		203-855-0400

	MAIL ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE
		STREET 2:		STE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardlytics, Inc.
		CENTRAL INDEX KEY:			0001666071
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
		IRS NUMBER:				263039436
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		675 PONCE DE LEON AVENUE, NE
		STREET 2:		SUITE 6000
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30308
		BUSINESS PHONE:		888-798-5802

	MAIL ADDRESS:	
		STREET 1:		675 PONCE DE LEON AVENUE, NE
		STREET 2:		SUITE 6000
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30308
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2019-01-29</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001666071</issuerCik>
        <issuerName>Cardlytics, Inc.</issuerName>
        <issuerTradingSymbol>CDLX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001419148</rptOwnerCik>
            <rptOwnerName>Canaan VIII LP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CANAAN PARTNERS</rptOwnerStreet1>
            <rptOwnerStreet2>285 RIVERSIDE AVENUE, SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>WESTPORT</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06880</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001552200</rptOwnerCik>
            <rptOwnerName>Canaan Partners VIII LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CANAAN PARTNERS</rptOwnerStreet1>
            <rptOwnerStreet2>285 RIVERSIDE AVENUE, SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>WESTPORT</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06880</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2019-01-29</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>750000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1618141</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">On January 29, 2019, Canaan VIII L.P. (the &quot;Canaan Fund&quot;) distributed, for no consideration, 750,000 shares of Common Stock of the issuer (the &quot;Shares&quot;) to its limited partners and to Canaan Partners VIII LLC (&quot;Canaan VIII&quot; and, together with the Canaan Fund, the &quot;Canaan Entities&quot;), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan VIII distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.</footnote>
        <footnote id="F2">Shares held directly by the Canaan Fund.  Canaan VIII is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively.  Canaan VIII disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24 to the Form 4 filed by the Reporting Persons on August 9, 2018)</remarks>

    <ownerSignature>
        <signatureName>Canaan VIII L.P., By: Canaan Partners VIII LLC, its general partner, By: /s/ Janine MacDonald, Attorney-in-Fact</signatureName>
        <signatureDate>2019-01-31</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>Canaan Partners VIII LLC, By: /s/ Janine MacDonald, Attorney-in-Fact</signatureName>
        <signatureDate>2019-01-31</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
